ATHE logo

ALTERITY THERAPEUTICS-ADR

ATHENASDAQ
🏆 #4371 by market capUS Equity
$118.01▲ $5.88 (+4.98%)
Simulated price
🔔
Track ATHE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.0%
7d▲ 2918.2%
14d▲ 3106.8%
30d▲ 2522.4%
ytd▲ 3658.3%
1y▲ 2785.3%
🏦Market Cap
$59M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
—
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$116.17 – $119.54
52-Week Range
$2.66 – $5.89
Volume
$2.66B
Avg Volume
$1.96B
Shares Outstanding
16.9M
Next Earnings
Dec 15, 2026

Fundamentals Snapshot

Annual Revenue
$28M
Last Q Revenue
$8M
P/E Ratio
-3.6
P/S Ratio
0.0x
EPS (TTM)
$-64.55
Dividend Yield
0.00%
Dilution (1yr)
+6.8%

Why Investors Own ATHE

  • ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 4% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ATHE logo

ALTERITY THERAPEUTICS-ADR

ATHE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.7%▲ +3.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$28M▲ +90.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$0▼ −100.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.1M▲ +6.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$37M▼ −$12M YoY
StockOtter · stockotter.space

About ALTERITY THERAPEUTICS-ADR

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$127.29
▲ +7.9% Upside
High Target$159.24
Low Target$102.10
Based on 36 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

ALTERITY THERAPEUTICS-ADR tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift ATHE price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ALTERITY THERAPEUTICS-ADR announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.